{"created":"2023-05-15T14:50:05.672563+00:00","id":68511,"links":{},"metadata":{"_buckets":{"deposit":"41adf0b4-4e12-4fb6-b849-f5175ced3202"},"_deposit":{"created_by":1,"id":"68511","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"68511"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00068511","sets":["10:28"]},"author_link":["672465","672466","672461","672464","672469","672462","672467","672463","672468"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2003-10-29","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"様々なコカイン類似体がPET用ドーパミントランスポーター(DAT)リガンドとして開発されてきたが、DATに対して高い親和性を有する化合物が同時にモノアミントランスポーター(MAT)に対しても、かなり高い親和性を有しているという欠点があった。近年、新規DATリガンドとしてKi値が17 nM, Kd値が0.09 nMでありMATに対する親和性の低い化合物PE2Iが提唱された。今回我々はLiAlH<SUB>4</SUB>を用いる従来法とシングルパスヨウ素法を用いたPE2Iの[<SUP>11</SUP>C]標識を行い、臨床用薬剤としての製造法を確立したので報告する。両法ともに、放射化学純度(95%以上)、比放射能(18.5 GBq/mmol以上)、核種純度(95%以上)、原料混入量(10mg/0.4GBq以下)、発熱試験(陰性)、無菌試験(陰性)などの臨床提供基準を満たす製品を得ることが出来た。また、後者の製法では50Ci/mmol以上の超高比放射能[<SUP>11</SUP>C]PE2Iを得ることができた。さらに、2つの方法で合成した[<SUP>11</SUP>C]PE2Iや主原料、主成分に対して急性毒性試験及び被爆線量測定も行った。","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"第43回日本核医学会総会","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"北條, 順子"}],"nameIdentifiers":[{"nameIdentifier":"672461","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"中尾, 隆士"}],"nameIdentifiers":[{"nameIdentifier":"672462","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"根本, 和義"}],"nameIdentifiers":[{"nameIdentifier":"672463","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"須原, 哲也"}],"nameIdentifiers":[{"nameIdentifier":"672464","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"鈴木, 和年"}],"nameIdentifiers":[{"nameIdentifier":"672465","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"中尾 隆士","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"672466","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"根本 和義","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"672467","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"須原 哲也","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"672468","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"鈴木 和年","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"672469","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"臨床用ドーパミントランスポーターリガンド[<SUP>11</SUP>C]PE2Iの製造法の確立","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"臨床用ドーパミントランスポーターリガンド[<SUP>11</SUP>C]PE2Iの製造法の確立"}]},"item_type_id":"10005","owner":"1","path":["28"],"pubdate":{"attribute_name":"公開日","attribute_value":"2006-06-19"},"publish_date":"2006-06-19","publish_status":"0","recid":"68511","relation_version_is_last":true,"title":["臨床用ドーパミントランスポーターリガンド[<SUP>11</SUP>C]PE2Iの製造法の確立"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T20:25:19.782340+00:00"}